Cargando…
A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
BACKGROUND: No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European countries. METHODS: We used country-spec...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712021/ https://www.ncbi.nlm.nih.gov/pubmed/23869204 http://dx.doi.org/10.1371/journal.pone.0066454 |
_version_ | 1782277003078008832 |
---|---|
author | Schuetz, C. Andy Alperin, Peter Guda, Swathi van Herick, Andrew Cariou, Bertrand Eddy, David Gumprecht, Janusz Nicolucci, Antonio Schwarz, Peter Wareham, Nick J. Witte, Daniel R. Smith, Ulf |
author_facet | Schuetz, C. Andy Alperin, Peter Guda, Swathi van Herick, Andrew Cariou, Bertrand Eddy, David Gumprecht, Janusz Nicolucci, Antonio Schwarz, Peter Wareham, Nick J. Witte, Daniel R. Smith, Ulf |
author_sort | Schuetz, C. Andy |
collection | PubMed |
description | BACKGROUND: No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European countries. METHODS: We used country-specific data from Denmark, France, Germany, Italy, Poland, and the United Kingdom to generate simulated populations of individuals aged 40–75 eligible for health checks in those countries (e.g. individuals without a previous diagnosis of diabetes, myocardial infarction, stroke, or serious chronic kidney disease). For each country, we used the Archimedes model to compare seven health check strategies consisting of assessments for diabetes, hypertension, lipids, and smoking. For patients diagnosed with vascular disease, treatment was simulated in a standard manner. We calculated the effects of each strategy on the incidence of type 2 diabetes, major adverse cardiovascular events (MACE), and microvascular complications in addition to quality of life, costs, and cost per quality-adjusted life-year (QALY). RESULTS: Compared with current care, health checks reduced the incidence of MACE (6–17 events prevented per 1000 people screened) and diabetes related microvasular complications (5–11 events prevented per 1000 people screened), and increased QALYs (31–59 discounted QALYs) over 30 years, in all countries. The cost per QALY of offering a health check to all individuals in the study cohort ranged from €14903 (France) to cost saving (Poland). Pre-screening the population and offering health checks only to higher risk individuals lowered the cost per QALY. Pre-screening on the basis of obesity had a cost per QALY of €10200 (France) or less, and pre-screening with a non-invasive risk score was similar. CONCLUSIONS: A vascular disease health check would likely be cost effective at 30 years in Denmark, France, Germany, Italy, Poland, and the United Kingdom. |
format | Online Article Text |
id | pubmed-3712021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37120212013-07-18 A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis Schuetz, C. Andy Alperin, Peter Guda, Swathi van Herick, Andrew Cariou, Bertrand Eddy, David Gumprecht, Janusz Nicolucci, Antonio Schwarz, Peter Wareham, Nick J. Witte, Daniel R. Smith, Ulf PLoS One Research Article BACKGROUND: No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European countries. METHODS: We used country-specific data from Denmark, France, Germany, Italy, Poland, and the United Kingdom to generate simulated populations of individuals aged 40–75 eligible for health checks in those countries (e.g. individuals without a previous diagnosis of diabetes, myocardial infarction, stroke, or serious chronic kidney disease). For each country, we used the Archimedes model to compare seven health check strategies consisting of assessments for diabetes, hypertension, lipids, and smoking. For patients diagnosed with vascular disease, treatment was simulated in a standard manner. We calculated the effects of each strategy on the incidence of type 2 diabetes, major adverse cardiovascular events (MACE), and microvascular complications in addition to quality of life, costs, and cost per quality-adjusted life-year (QALY). RESULTS: Compared with current care, health checks reduced the incidence of MACE (6–17 events prevented per 1000 people screened) and diabetes related microvasular complications (5–11 events prevented per 1000 people screened), and increased QALYs (31–59 discounted QALYs) over 30 years, in all countries. The cost per QALY of offering a health check to all individuals in the study cohort ranged from €14903 (France) to cost saving (Poland). Pre-screening the population and offering health checks only to higher risk individuals lowered the cost per QALY. Pre-screening on the basis of obesity had a cost per QALY of €10200 (France) or less, and pre-screening with a non-invasive risk score was similar. CONCLUSIONS: A vascular disease health check would likely be cost effective at 30 years in Denmark, France, Germany, Italy, Poland, and the United Kingdom. Public Library of Science 2013-07-15 /pmc/articles/PMC3712021/ /pubmed/23869204 http://dx.doi.org/10.1371/journal.pone.0066454 Text en © 2013 Schuetz et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Schuetz, C. Andy Alperin, Peter Guda, Swathi van Herick, Andrew Cariou, Bertrand Eddy, David Gumprecht, Janusz Nicolucci, Antonio Schwarz, Peter Wareham, Nick J. Witte, Daniel R. Smith, Ulf A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis |
title | A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis |
title_full | A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis |
title_fullStr | A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis |
title_full_unstemmed | A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis |
title_short | A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis |
title_sort | standardized vascular disease health check in europe: a cost-effectiveness analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712021/ https://www.ncbi.nlm.nih.gov/pubmed/23869204 http://dx.doi.org/10.1371/journal.pone.0066454 |
work_keys_str_mv | AT schuetzcandy astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT alperinpeter astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT gudaswathi astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT vanherickandrew astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT carioubertrand astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT eddydavid astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT gumprechtjanusz astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT nicolucciantonio astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT schwarzpeter astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT warehamnickj astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT wittedanielr astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT smithulf astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT schuetzcandy standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT alperinpeter standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT gudaswathi standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT vanherickandrew standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT carioubertrand standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT eddydavid standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT gumprechtjanusz standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT nicolucciantonio standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT schwarzpeter standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT warehamnickj standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT wittedanielr standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis AT smithulf standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis |